Arbutus Biopharma(ABUS)
搜索文档
Arbutus Biopharma(ABUS) - 2019 Q4 - Earnings Call Transcript
2020-03-06 00:13
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2019 Earnings Conference Call March 5, 2020 8:45 AM ET Company Participants Pam Murphy - IR Bill Collier - President and CEO Dave Hastings - CFO Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Mayank Mamtani - B. Riley Keay Nakae - Chardan Madhu Kumar - Robert W. Baird Operator Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-En ...
Arbutus Biopharma(ABUS) - 2019 Q3 - Quarterly Report
2019-11-07 01:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 | --- | --- | --- | |---------------------------------------------------|--------------------------------------------------- ...
Arbutus Biopharma(ABUS) - 2019 Q3 - Earnings Call Transcript
2019-11-06 23:51
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2019 Earnings Conference Call November 6, 2019 8:45 AM ET Company Participants Pam Murphy - IR Consultant Bill Collier - President & CEO David Hastings - CFO Gaston Picchio - CDO Michael Sofia - CSO Conference Call Participants Neil Panchal - JMP Securities Keay Nakae - Chardan Operator Ladies and gentlemen, thank you for standing by and welcome to the Arbutus Biopharma Corporation 2019 Third Quarter Financial Results and Corporate Update. At this time, all lin ...
Arbutus Biopharma(ABUS) - 2019 Q2 - Earnings Call Transcript
2019-08-06 03:08
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2019 Results Earnings Conference Call August 5, 2019 8:45 AM ET Company Participants Pam Murphy - IR Consultant William Collier - President, CEO David Hastings - CFO & CAO Gaston Picchio - Chief Development Officer Michael Sofia - Chief Scientific Officer Conference Call Participants Keay Nakae - Chardan Jeffrey Tan - B. Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 Second Quarter Financial Results and ...
Arbutus Biopharma(ABUS) - 2019 Q2 - Quarterly Report
2019-08-06 00:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 | --- | --- | --- | --- | |---------------------------------------------------|-------------------------------------------------- ...
Arbutus Biopharma(ABUS) - 2019 Q1 - Earnings Call Transcript
2019-05-07 09:34
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 6, 2019 4:30 PM ET Company Participants Pam Murphy - IR Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - CFO Conference Call Participants Keay Nakae - Chardan Mayank Mamtani - B Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Conference Call. [Ope ...
Arbutus Biopharma(ABUS) - 2019 Q1 - Quarterly Report
2019-05-07 05:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 | --- | --- | |--------------------------------------------------------------------------------------------------------|-------- ...
Arbutus Biopharma(ABUS) - 2018 Q4 - Earnings Call Transcript
2019-03-08 10:24
Arbutus Biopharma Corp. (NASDAQ:ABUS) Q4 2018 Results Conference Call March 7, 2019 4:30 PM ET Company Participants Pam Murphy - Investor Relations Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - Chief Financial Officer Conference Call Participants Katherine Xu - William Blair Keay Nakae - Chardan Mayank Mamtani - B Riley Operator Good day, ladies and gentlemen. And welcome to Arbutus Biopharma Fourth quarter and 2018 Year-End Conference Cal ...